Table 1

Baseline characteristics and scores on clinical scales and cognitive testing at baseline and at 12-month follow-up and change in scores between time points for Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) groups

AD (n=100)DLB (n=58)p
Gender (M:F)
 M48 (48%)37 (64%)0.06
 F52 (52%)21 (36%)
Age in years at 123I-FP-CIT SPECT session74.9 (7.3)74.2 (6.1)0.53
Cornell Scale for Depression in Dementia (baseline)3.8 (3.3)6.6 (3.4)<0.001
Cholinesterase inhibitor82 (82%)45 (76%)0.50
Memantine9 (9%)2 (3%)0.19
Neuroleptic medication4 (4%)9 (16%)0.01
Clinical Dementia Rating (baseline)1.2 (0.69)1.3 (0.66)0.3
MMSE score (SD)
 Baseline21.5 (4.5)21.4 (3.9)0.85
 Follow-up19.0 (6.2)18.5 (6.0)0.65
 Change2.6 (4.0)3.1 (4.3)0.40
CAMCOG score (SD)
 Baseline66.3 (15.6)66.0 (13.5)0.89
 Follow-up59.5 (20.3)56.3 (19.7)0.35
 Change7.5 (10.6)9.0 (11.9)0.429
NPI score (SD)
 Baseline9.7 (10.3)19.8 (14.6)<0.001
 Follow-up12.3 (13.3)24.2 (17.4)<0.001
 Change2.5 (14.8)3.8 (15.5)0.59
NPI-carer score (SD)
 Baseline5.8 (6.0)10.8 (8.0)<0.001
 Follow-up5.8 (5.7)11.8 (8.6)<0.001
 Change−0.05 (6.4)0.8 (7.1)0.44
Fluctuations
 Baseline0.6 (2.1)6.0 (4.5)<0.001
 Follow-up0.4 (1.7)6.9 (4.1)<0.001
 Change−0.2 (2.4)0.8 (4.1)0.07
CAMCOG executive function
 Baseline11.9 (5.2)11.1 (4.7)0.33
 Follow-up10.5 (5.4)9.4 (5.0)0.24
 Change1.5 (3.6)1.4 (4.0)0.83
  • Data are presented as mean (SD) or number (%). p=p Values (analysis of variance).

  • CAMCOG, Cambridge Cognitive Examination; MMSE, Mini-Mental State Examination; NPI, Neuropsychiatric Inventory.